A
226.10
2.15 (0.96%)
| Penutupan Terdahulu | 223.95 |
| Buka | 224.00 |
| Jumlah Dagangan | 324,906 |
| Purata Dagangan (3B) | 675,926 |
| Modal Pasaran | 13,814,293,504 |
| Harga / Pendapatan (P/E Ke hadapan) | 43.67 |
| Harga / Jualan (P/S) | 16.65 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 11 Feb 2026 |
| Margin Keuntungan | -92.67% |
| Margin Operasi (TTM) | -103.23% |
| EPS Cair (TTM) | -6.79 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 5.30% |
| Nisbah Semasa (MRQ) | 1.04 |
| Aliran Tunai Operasi (OCF TTM) | -218.93 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -133.44 M |
| Pulangan Atas Aset (ROA TTM) | -22.39% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Ascendis Pharma A/S | Menaik | Menaik |
AISkor Stockmoo
2.0
| Konsensus Penganalisis | 4.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -0.5 |
| Purata Bergerak Teknikal | 5.0 |
| Osilator Teknikal | -0.5 |
| Purata | 2.00 |
|
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology which includes TransCon PTH, TransCon CNP, and others. It operates in North America, Europe, and Rest of the world and derives the majority of its revenue from North America. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| % Dimiliki oleh Orang Dalam | 0.78% |
| % Dimiliki oleh Institusi | 113.63% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 342.00 (Barclays, 51.26%) | Beli |
| Median | 275.00 (21.63%) | |
| Rendah | 260.00 (B of A Securities, 14.99%) | Beli |
| Purata | 295.29 (30.60%) | |
| Jumlah | 7 Beli | |
| Harga Purata @ Panggilan | 221.83 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| RBC Capital | 03 Mar 2026 | 275.00 (21.63%) | Beli | 239.22 |
| 20 Jan 2026 | 250.00 (10.57%) | Beli | 215.58 | |
| Oppenheimer | 12 Feb 2026 | 262.00 (15.88%) | Beli | 218.10 |
| Wedbush | 12 Feb 2026 | 273.00 (20.74%) | Beli | 218.10 |
| B of A Securities | 30 Jan 2026 | 260.00 (14.99%) | Beli | 226.10 |
| Barclays | 28 Jan 2026 | 342.00 (51.26%) | Beli | 222.45 |
| Wells Fargo | 20 Jan 2026 | 330.00 (45.95%) | Beli | 215.58 |
| 09 Jan 2026 | 322.00 (42.41%) | Beli | 202.99 | |
| TD Cowen | 07 Jan 2026 | 325.00 (43.74%) | Beli | 213.28 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 04 Feb 2026 | Pengumuman | Ascendis Pharma to Report Full Year 2025 Financial Results and Provide Business Update on February 11, 2026 |
| 09 Jan 2026 | Pengumuman | Ascendis Pharma Provides Business and Strategic Roadmap Update at 44th Annual J.P. Morgan Healthcare Conference |
| 08 Jan 2026 | Pengumuman | Week 52 COACH Trial Topline Results Confirm Consistent and Durable Treatment Benefits in Children with Achondroplasia (ACH) |
| 05 Jan 2026 | Pengumuman | Ascendis Pharma to Participate in the 44th Annual J.P. Morgan Healthcare Conference |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |